CASI Pharmaceuticals reported the termination of its Global Chief Medical Officer and is actively searching for a replacement, temporarily reallocating clinical oversight to its China Chief Medical Officer. Concurrently, the company closed the final tranche of a $20 million convertible note financing, providing near-term liquidity but introducing dilution risks. CASI's business centers on hematology oncology and autoimmune therapeutics, balancing licensed commercial products like EVOMELA® with its clinical-stage pipeline candidate CID-103. Regulatory setbacks, including license withdrawal of FOLOTYN in China, and ongoing supply disputes have constrained growth. The firm remains challenged by negative operating cash flow and low liquidity despite efforts to advance domestically produced alternatives and pipeline progress.